Pharmaceutical manufacturing company IDT Australia has announced that it has been granted a Medicinal Cannabis Manufacturing Licence by the Department of Health – Office of Drug Control.
The licence will allow IDT to manufacture extracts and tinctures of cannabis and cannabis resin, as well as to package, transport, store, and supply the drug.
IDT’s Chief Executive Officer Dr David Sparling, said IDT’s manufacturing and packaging facilities already have in place a Good Manufacturing Practices (GMP) licence issued by the Therapeutic Goods Administration (TGA) as well as the requisite Poisons Licensure for handling certain Schedule 8 and 9 drugs.
“We are extremely pleased to have secured a Medicinal Cannabis Manufacturing Licence from the Office of Drug Control” Mr Sparling continued.
“With IDT’s long established facilities and expertise in GMP pharmaceutical manufacturing, a licence in our own right to manufacture Medicinal Cannabis products puts IDT in a very strong position in the exciting and rapidly growing global medicinal cannabis market.”